The phase 2 ImmunoCobiVem trial enrolled patients with unresectable or metastatic BRAFV600 mutant melanoma to receive BRAF/MEK inhibitor therapy with vemurafenib and cobimetinib for three months [81]. The gene discussed is MAP2K7; the disease is melanoma.